Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.

Eli Lilly’s total deal value with Rznomics could exceed $1.3 billion ... Concerns Over CVS Setback Are Overblown, Analysts Say The collaboration focuses on discovering and developing RNA ...

Co-development of precision RNA therapeutics for inherited hearing loss treatment SEONGNAM, South Korea, May 15, 2025 /PRNewswire/ -- Rznomics ... collaboration and licensing agreement with Eli ...

SEONGNAM, South Korea, May 15, 2025 /PRNewswire/ -- Rznomics Inc., a South ... into a strategic global research collaboration and licensing agreement with Eli Lilly and Company to develop and ...

2025 /PRNewswire/ -- Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, announced today that it has entered into a strategic global research ...

Eli Lilly is strengthening its position in genetic medicine for hearing loss through a new collaboration with South Korea-based biotech Rznomics. The agreement, centred on the development of RNA ...